Spinal Muscular Atrophy

New England CEPAC

ICER will develop a report assessing the comparative clinical effectiveness and value of AVXS-101 (Novartis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).

Associated Meetings

March 7, 2019 10am-4pm ET

Omni Parker House
60 School Street
Boston, MA 02108

The New England CEPAC will convene to deliberate and vote on ICER's report on treatments for SMA.


Key Dates

Associated Materials

07/31/2018 – 08/17/2018
Open Input Period

08/22/2018

08/22/2018 – 09/12/2018
Public Comments

08/22/2018

09/19/2018
Revised Scoping Document

12/20/2018
Draft Evidence Report

12/20/2018
Draft Voting Questions

12/20/2018 – 01/31/2019
Public Comments

02/21/2019
Evidence Report

02/21/2019
Revised Voting Questions

02/21/2019
Response to Comments

03/07/2019
Meeting Agenda

03/07/2019
Evidence Presentation

03/28/2019
Final Evidence Report and Meeting Summary